Pictured: Yu Chen

Yu Chen, MD, PhD

Medical Oncologist

Titles

Associate Attending Physician

Clinical Expertise

Prostate Cancer; Bladder Cancer

Share

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Mon–Fri, 8:00 a.m.–6:00 p.m., (Eastern time)
Accepted Insurance Providers

Dr. Chen accepts the following list of insurance providers. Select your insurance provider to see more details.

Aetna

Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.

Blue Distinction Center

Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.

Health Insurance Exchanges

We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.

CIGNA

Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.

  • If you are a New York State resident: Please ask your insurance if you need a one-time referral.
  • If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
EmblemHealth (including GHI, HIP, ConnectiCare, and Vytra)

Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:

  • Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
  • Please call Emblem to confirm if your specific plan is in-network.

For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page

Empire Blue Cross Blue Shield

Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:

  • Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
  • Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
HealthFirst

Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.

HealthSmart

Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.

Horizon Blue Cross Blue Shield of New Jersey

For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations.  Please call Horizon to confirm if your plan is in-network in NY. 

Humana

Memorial Sloan Kettering is a designated Center of Excellence by Humana.

Interlink Health Services

Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.

Lifetrac

Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.

MagnaCare

Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.

Medicare & Medicaid

For information about Medicare and Medicaid, please visit this page

Multiplan/Beech Street/PHCS

Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.

Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.

Multiple Insurance Plans

If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.

MVP

Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.

New York State Employee Health Insurance Plan (Empire Plan)

Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.

Oscar

Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier. 

Other Blue Cross Blue Shield plans

Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.

Other Coverage Options

We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:

  • AXA Assistance USA
  • Beech Street
  • Integrated Health Plans
  • National Health Administrators
  • National Preferred Provider Network
  • UnitedHealthcare's Cancer Resource Services
  • United Resource Network
  • Veterans Choice Program
Oxford

Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.

World Trade Center Health Program

Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.

QualCare

Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.

Specialty Care Management

Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.

TRICARE

Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.

UnitedHealthcare

Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.

UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.

United does not include us in any of the plans you can buy through the insurance exchanges.

Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.

Contact and Location

Locations map
Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.

See all locations

About Me

Education

MD, Cornell University Medical College

Residencies

Internal Medicine - Brigham and Women's Hospital

Fellowships

Medical Oncology - Memorial Sloan Kettering Cancer Center

Board Certifications

Internal Medicine, Medical Oncology

As a physician-scientist and board-certified medical oncologist. I am devoted to the care of cancer patients in the clinic and to gaining knowledge in the laboratory of how cancers develop. My research focus is on the pathogenesis and treatment of prostate cancer. I am involved in a multidisciplinary effort with oncologists, pathologist, and surgeons to analyze tumor tissues and to develop clinical trials. My laboratory in the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center focuses on the study of critical drivers in prostate cancer pathogenesis using cell, tissue, and mouse models.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Genitourinary Oncology Service doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

View Dr. Chen's Lab

Chen Y, Shamu T, Chen H, Besmer P, Sawyers CL, Chi P.. Visualization of the interstitial cells of cajal (ICC) network in mice. J Vis Exp Dec 31, 2011; 53 :

Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL.. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.. Cancer Cell 2011; 19 :575-86

Chen Y., Arora, V.K. Sawyers C.L. (2011). Molecular Biology of Prostate Cancer. In: Devita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9 ed. Philadelphia: Lippincott Williams & Wilkins.

Read more

Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD, Sawyers CL.. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 2010; 467 :849-53

Chen Y, Sawyers CL. Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers.. Cancer Cell 2010; 17 :415-6

Chen Y, Clegg NJ, Scher HI.. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncology 2009; 10 :981-91

Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL.. Development of a second-generation antiandrogen for treatment of advanced prostate cancer.. Science 2009; 324 :787-90

Welsbie D, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers CL. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Research 2009; 69 :958-66

Chen Y, Sawyers CL, Scher HI.. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008; 8 :440-448

Chen Y, Sawyers CL. Molecular Biology of Prostate Cancer. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology, 8th ed. Philadelphia: Lippincott Williams & Wilkins; 1385-91.

Ghia KK, Chen Y, Milner DA Jr, Fisher DC. Challenging manifestations of malignancies. Case 2. Langerhans cell histiocytosis presenting with a skin rash.. Journal of Clinical Oncology 2004; 22 :3640-3642

Rajagopal A, Pant AC, Simon SM, Chen Y.. In vivo analysis of human multidrug resistance protein 1 (MRP1) activity using transient expression of fluorescently tagged MRP1.. Cancer Research 2002; 62 :391-396

Chen Y, Pant AC, Simon SM.. P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells.. Cancer Research 2001; 61 :391-396

Chen Y, Simon SM.. In situ biochemical demonstration that P-glycoprotein is a drug efflux pump with broad specificity.. The Journal of Cell Biology 2000; 148 :863-879

Chen Y, Schindler M, Simon SM.. A mechanism for tamoxifen-mediated inhibition of acidification. Journal of Biological Chemistry 1999; 274 :18364-18373

Altan N, Chen Y, Schindler M, Simon SM.. Tamoxifen inhibits acidification in cells independent of the estrogen receptor. . Proceedings of the National Academy of Sciences of the United States of America 1999; 96 :44432-4438

Altan N, Chen Y, Schindler M, Simon SM.. Defective acidification in human breast tumor cells and implications for chemotherapy. Journal of Experimental Medicine 1998; 187 :1583-1598

Chen Y, Gross P, Ramakrishna V, Rabitz H, Mease K, Singh H. Control of classical regime molecular objectives - applications of tracking and Variations of the theme. Automatica 1997; 33 :1617-1633

Chen Y., Gross P., Ramakrishn V., Rabitz H., Mease K., Singh H. Selective excitation of molecular eigenstates using state-dependent optical field design. Chemical Physics Letters 1996; 252 :447-456

Chen Y, Gross P, Ramakrishna V, Rabitz H., Mease K, Singh H. Competitive tracking of molecular objectives described by quantum mechanics. Journal of Chemical Physics 1995; 102 :8001-8010

 

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Yu Chen discloses the following relationships and financial interests:

  • Merck & Co Inc.
    Provision of Services
  • Myovant Sciences
    Ownership / Equity Interests
  • Oric Pharmaceuticals
    Intellectual Property Rights; Ownership / Equity Interests

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures